The elite award grants special pricing and pre-negotiated terms for Stago's complete coagulation solutions to Premier's ASCEND program members, including high-quality diagnostic instruments and automation-ready reagents.
"Our long-standing partnership with Premier means that our mutual customers benefit from world-class coagulation technologies and expertise, and now Premier's ASCEND members have the added exclusive advantage of pre-negotiated conditions," noted Stephane Zamia, CEO of Diagnostica Stago, Inc. "Ultimately, this means that we can all remain focused on managing and improving healthcare, together."
Stago's focus on coagulation and coagulation technologies includes STA® Hemostasis Analyzers, which range from fully integrated, stand-alone units to manual, benchtop models, depending on the facility's connectivity and throughput needs. Each is capable of performing clotting, chromogenic and immunological assays, and also features patented VDS (Viscosity-based Detection System) electromechanical clot detection technology to eliminate interferences and standardize results across all STA Hemostasis Analyzers. Additionally, a wide range of high-quality, automation-ready reagent test kits are optimized for routine analysis as well as research use. In addition to his leadership in coagulation, Stago is at the forefront of the collaboration with Pharma industry with regards to New oral anticoagulant.